The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials

References

• Hagiwara N. Inflammation and atrial fibrillation. Circulation J 2010;74:246-7
   PubMed Web of Science ®Google Scholar
• Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 2006;47:51-3
   PubMedGoogle Scholar
• Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nature Med 2010;16:470-5
   PubMed Web of Science ®Google Scholar
• Liu T, Li LJ, Korantzopoulos P, et al. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70
   PubMed Web of Science ®Google Scholar
• Fauchier L, Pierre B, Labriolle AD, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Moher D, Schulz KF, Altman D. CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91
   PubMed Web of Science ®Google Scholar
• Shi W, Liu ZZ, Su L, et al. A meta-analysis on randomized controlled trials of statins to prevent atrial fibrillation. Chin J Evid-based Med 2009;9:570-3
   Google Scholar
• Mai JZ, Li H, Fang JQ, et al. Estimation of fail-safe number in meta-analysis. J Evid Base Med 2006;6:297-303
   Google Scholar
• Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement – quality of reporting of meta-analyses. Lancet 1999;354:1896-900
   PubMed Web of Science ®Google Scholar
• Sun YF, Mei YQ, Ji Q, et al. Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Zhonghua Yi Xue Za Zhi 2009;89:2988-91
   PubMedGoogle Scholar
• Pelleqrini CN, Vittinghoff E, Lin F, et al. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 2009;95:704-8
   PubMed Web of Science ®Google Scholar
• Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-2
   PubMed Web of Science ®Google Scholar
• Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150:1064
   PubMed Web of Science ®Google Scholar
• Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-3
   PubMed Web of Science ®Google Scholar
• Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study. Circulation 2006;114:1455-61
   PubMed Web of Science ®Google Scholar
• Garcia-Fernandez A, Marin F, Mainar L, et al. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;98:1299-300
   PubMed Web of Science ®Google Scholar
• Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008;156:373
   PubMed Web of Science ®Google Scholar
• Xia W, Yin ZM, Li JJ, et al. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. PACE 2009;32:1562-6
   Google Scholar
• Ji Q, Mei Y, Wang X, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009;73:2244-9
   PubMed Web of Science ®Google Scholar
• Almroth H, Hoglund N, Boman K, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009;30:827-33
   PubMed Web of Science ®Google Scholar
• Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54:2023-31
   PubMed Web of Science ®Google Scholar
• Tsai CT, Lai LP, Hwang JJ, et al. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: A prospective randomized trial. Am Heart J 2008;156:65-70
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009;30:2327-36
   PubMed Web of Science ®Google Scholar
• Negi S, Shukrullah I, Veledar E, et al. Statin therapy for the prevention of atrial fibrillation (SToP AF trial). J Cardiovasc Electrophysiol 2010;1-6
   PubMed Web of Science ®Google Scholar
• Mclean DS, Ravid S, Blazing M, et al. Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A-Z) trials. Am Heart J 2008;155:298-302
   PubMed Web of Science ®Google Scholar
• Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006;113:427-37
   PubMed Web of Science ®Google Scholar
• Smit MD, Van Gelder IC. Is inflammation a risk factor for recurrent atrial fibrillation? Europace 2009;11:138-9
   PubMed Web of Science ®Google Scholar
• Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010;7:438-44
   PubMed Web of Science ®Google Scholar
• Mathew ST, Patel J, Joseph S. Atrial fibrillation: mechanistic insights and treatment options. Eur J Intern Med 2009;20:672-81
   PubMed Web of Science ®Google Scholar
• Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10
   PubMed Web of Science ®Google Scholar
• Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26:2083-92
   PubMed Web of Science ®Google Scholar
• Bourassa MG. Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol 2005;45:720-1
   PubMed Web of Science ®Google Scholar
• Bielecka-Dabrowa A, Goch JH, Rysz J, et al. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Lipids Health Dis 2010;9:21
   PubMed Web of Science ®Google Scholar
• Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007;53:1652-7
   PubMed Web of Science ®Google Scholar
• Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008;51:68-74
   PubMed Web of Science ®Google Scholar
• Chang JP, Chen MC, Liu WH, et al. Atrial myocardial nox2 containing NADPH oxidase activity contribution to oxidative stress in mitral regurgitation: potential mechanism for atrial remodeling. Cardiovasc Pathol 2011;20:99-106
   PubMed Web of Science ®Google Scholar
• Di Napoli P, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66:462-71
   PubMed Web of Science ®Google Scholar
• Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933-9
   PubMed Web of Science ®Google Scholar
• Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008;117:344-5
   PubMed Web of Science ®Google Scholar
• Xu MW, Yuan GH, Wei FP. Effect of atorvastatin in patients with chronic heart failure – insights from randomized clinical trials. Arch Med Sci 2010;6:866-73
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP, Kjeldsen SE, et al. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
   PubMed Web of Science ®Google Scholar
• Banach M, Goch JH, Ugurlucan M, et al. Statins in the prevention of postoperative atrial fibrillation: is there really no effect? Am Heart J 2008;155:e53
   PubMed Web of Science ®Google Scholar
• Banach M, Kourliouros A, Reinhart KM, et al. Postoperative atrial fibrillation – what do we really know? Curr Vasc Pharmacol 2010;8:553-72
   PubMed Web of Science ®Google Scholar